risankizumab SC

DRUG6 trials

Conditions

Crohn DiseaseCrohn's DiseaseUlcerative Colitis (UC)

Phase 2

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

CompletedNCT02031276

AbbVieCrohn Disease

Start: 2014-02-28End: 2016-11-30Updated: 2018-11-23

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

CompletedNCT03398148

AbbVieUlcerative Colitis (UC)

Start: 2018-03-07End: 2023-05-11Updated: 2025-01-16

Phase 3

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

CompletedNCT03104413

AbbVieCrohn's Disease

Start: 2017-12-18End: 2021-05-19Updated: 2022-06-14

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Active, not recruitingNCT03105102

AbbVieCrohn's Disease

Start: 2018-04-09End: 2026-05-31Updated: 2025-08-14

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

CompletedNCT03105128

AbbVieCrohn's Disease

Start: 2017-05-10End: 2021-04-14Updated: 2022-07-06

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Active, not recruitingNCT06063967

AbbVieCrohn's Disease

Start: 2023-11-15End: 2027-03-31Updated: 2025-09-09

Journal of Crohn s and Colitis2026-01-01

Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment.

2025-09-13

Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials.

2025-06-092 citations

Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis

Journal of Crohn s and Colitis2025-04-011 citations

Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment.

2025-02-034 citations

Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies

Journal of Crohn s and Colitis2025-01-019 citations

DOP016 Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension

Journal of Crohn s and Colitis2025-01-011 citations

P0390 Development, internal, and external validation of a novel endoscopic activity score for evaluation of Crohn’s disease (EASE-CD)

Journal of Crohn s and Colitis2025-01-01

Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn’s Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies

Journal of Crohn s and Colitis2024-11-012 citations

Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn’s Disease

Gastro Hep Advances2024-09-061 citations

Content Validity and Psychometric Evaluation of the Crohn's Symptom Severity (CSS) Questionnaire in Patients with Moderately to Severely Active Crohn's Disease.

2024-08-06

Risankizumab for Ulcerative Colitis

JAMA2024-07-2287 citations

Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies.

2024-03-074 citations

OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study

Journal of Crohn s and Colitis2024-01-0116 citations

DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension

Journal of Crohn s and Colitis2024-01-017 citations

P862 Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials

Journal of Crohn s and Colitis2024-01-01

DOP76 Individual and comprehensive symptom resolution after induction and maintenance therapy with risankizumab in patients with moderately to severely active Ulcerative Colitis: A post-hoc analysis of INSPIRE and COMMAND studies

Journal of Crohn s and Colitis2024-01-01

P741 Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn’s disease

Journal of Crohn s and Colitis2024-01-01

P683 Economic impact of achieving mucosal healing on UC-related hospitalisations and work productivity in patients with moderately to severely active UC: A post-hoc analysis of risankizumab Phase 2b/3 trials

Journal of Crohn s and Colitis2024-01-01

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial

Journal of Crohn s and Colitis2023-10-0413 citations

29 more papers not shown

risankizumab SC

Sponsors

Conditions

Phase 2

Phase 3

Related Papers